MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-15-2026
Vivos Therapeutics Operating Income 2011-2026 | VVOS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Vivos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.9 M | -11.2 M | -17.3 M | -25 M | -20.4 M | -12 M | -10.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.6 M | -25 M | -16.6 M |
Quarterly Operating Income Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 M | -4.86 M | -3.92 M | - | -2.64 M | -1.94 M | -3.78 M | - | -3.64 M | -4.52 M | -5 M | - | -5.41 M | -6.96 M | -6.82 M | - | -5.5 M | -4.06 M | -3.41 M | - | -1.82 M | -1.42 M | -2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.42 M | -6.96 M | -4.06 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Bruker Corporation
BRKR
|
253 M | $ 39.25 | -0.58 % | $ 5.85 K |  USA |
 |
Align Technology
ALGN
|
608 M | $ 185.82 | -0.38 % | $ 13.9 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 12.62 | -0.28 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.61 | 3.15 % | $ 38 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.57 | 1.42 % | $ 134 M |  France |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.92 | -5.36 % | $ 70.8 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 63.96 | -1.01 % | $ 94.7 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 10.57 | 1.0 % | $ 299 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
9.66 M | $ 25.34 | -1.46 % | $ 214 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.69 | -1.82 % | $ 7.46 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Stryker Corporation
SYK
|
4.89 B | $ 337.06 | -1.22 % | $ 129 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.75 | -6.16 % | $ 393 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 92.66 | -2.0 % | $ 12.5 B | USA |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 24.94 | -1.62 % | $ 570 M | USA |
 |
TELA Bio
TELA
|
-33.8 M | $ 0.65 | -0.61 % | $ 30.5 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.98 | 2.06 % | $ 1.2 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.58 | 14.81 % | $ 1.18 B | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 20.2 | -2.23 % | $ 1.37 B | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.52 | 5.16 % | $ 173 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.03 | -0.96 % | $ 17.4 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.83 | -1.46 % | $ 388 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 56.99 | 0.62 % | $ 1.67 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 38.09 | -3.42 % | $ 1.18 B | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 64.69 | -0.69 % | $ 3.53 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 88.52 | 0.66 % | $ 3.07 B | USA |